The recycling activity of cytidine deaminase (CDA) within the pyrimidine salvage pathway is essential to DNA and RNA synthesis. As such, CDA deficiency can lead to replicative stress, notably in Bloom syndrome. Alternatively, CDA also can deaminate cytidine and deoxycytidine analog-based therapies, such as gemcitabine. Thus, CDA overexpression is often associated with lower systemic, chemotherapy-related, adverse effects but also with resistance to treatment. Considering the increasing interest of CDA in cancer chemoresistance, the aims of this review are to describe CDA structure, regulation of expression, and activity, and to report the therapeutic strategies based on CDA expression that recently emerged for tumor treatment.

中文翻译：

---

胞嘧啶脱氨酶在人类疾病中的新兴作用：治疗的新机会？

嘧啶挽救途径中胞嘧啶脱氨酶（CDA）的再循环活性对于DNA和RNA合成至关重要。因此，CDA缺乏会导致复制压力，特别是在Bloom综合征中。备选地，CDA还可以使基于胞嘧啶核苷和脱氧胞苷类似物的疗法如吉西他滨脱氨基。因此，CDA过表达通常与较低的全身性，化疗相关的不良反应有关，但也与对治疗的抗性有关。考虑到CDA对癌症化学抗药性的日益增长的兴趣，本文的目的是描述CDA的结构，表达的调节和活性，并报告基于CDA表达的治疗策略，该策略最近在肿瘤治疗中出现。